Reumed Sp. z o.o. — Clinical Trial Site

68 Registered trials

22 Currently recruiting

Organisation

Reumed Sp. z o.o.

Location

Lublin, Poland

Identifier

ORG-100042570

Address

Ul. Onyksowa 10, 20-582, Poland

Departments

-
„Reumed Sp. z o.o.” is a medical entity regist. in OMS and its medical facility is Zespol Poradni S
#40037: Zespol Poradni Specjalistycznych REUMED, Filia nr 1 Wallenroda
#40037: Zespol Porani Specjalistycznych Reumed Filia nr 1 Wallenroda
#40037:Zespol Poradni Specjalistycznych REUMED, Filia nr 1 Wallenroda
#7809: Rheumatology
2203:Reumatologia
2305: NA
2305: Reumatologia
2317
40037: Zespol Poradni Specjalistycznych REUMED, Filia nr 1 Wallenroda
410:Zespol Poradni Specjalistycznych REUMED, Filia nr 1 Wallenroda
Filia nr 1 Wallenroda
N/A
n/d
NA
Nd.
Not applicable
Outpatient Clinic
PL10015: Zespol Poradni Specjalistycznych REUMED ONYKSOWA Filia nr 2
PL10019_REUMED Zespol Poradni Specjalistycznych Filia nr 2
PL10021: Rheumatology
PL10021: Zespol Poradni Specjalistycznych REUMED ONYKSOWA Filia nr 2
Poradnia endokrynologicz na i diabetologiczna
Poradnia endokrynologiczna i diabetologiczna
Reumed Sp. Z O. O.
Reumed Sp. z o.o.
Reumed Spółka z o.o.
Reumed Zespol Poradni Specjalistycznych Filia nr 1
Rheumatology
Rheumatology Clinic
Zespol Poradni Specjalistycznych REUMED Filia nr 1
Zespol Poradni Specjalistycznych REUMED, Filia nr 1 Wallenroda
Zespol Poradni Specjalistycznychnych REUMED Filia nr1
Zespół Poradni Specjalistycznych - ONYKSOWA Filia nr 2
Zespół Poradni Specjalistycznych REUMED
Zespół Poradni Specjalistycznych REUMED Filia nr 1 WALLENRODA
Zespół Poradni Specjalistycznych Reumed Filia nr 1
Zespół Poradni Specjalistycznych Reumed Filia nr 1 Wallenroda
Zespół Poradni Specjalistycznych REUMED WALLENRODA Filia nr 1
Zespół Poradni Specjalistycznych REUMED- Filia nr 1 Wallenroda
Zespół Poradni Specjalistycznych REUMED, Filia nr 1 Wallenroda
Zespół Poradni Specjalistycznych Reumed, Filia nr1 Wallenroda
Zespół Poradni Specjalistycznych, REUMED, Filia nr 1 Wallenroda

Clinical trials at this site (68)

Search interface

A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting

2023-508191-11-00 Systemic lupus erythematosus (SLE) 5 2024-11-28
Long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus (OPUS OLE) Recruiting

2024-514354-67-00 Systemic lupus erythematosus 5 2024-11-01
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the i… Recruiting

2023-504417-67-00 Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiog 6 2020-12-22
A clinical study of tulisokibart in people with rheumatoid arthritis (MK-7240-014) Ended

2025-521745-25-00 Rheumatoid Arthritis 4 2025-11-06
Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease Ended

2024-516295-14-00 Treatment of Sjögren’s disease 4 2025-09-17
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination wi… Ended

2024-519945-31-00 Type 1 Diabetes 5 2025-08-21
Proof of Concept trial with CIT-013 in Rheumatoid Arthritis Ended

2024-517356-35-00 Moderately Active Rheumatoid Arthritis 4 2025-07-29
A Phase 2b to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With ACPA-Positive Rheumatoid Arthritis Ended

2024-515973-82-00 ACPA-Positive Rheumatoid Arthritis 4 2025-06-23
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended

2024-516609-22-00 Primary Sjögren’s Disease 5 2025-04-15
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended

2023-509239-19-00 Active Psoriatic Arthritis 5 2025-04-03
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu… Ended

2023-508077-85-00 Polymyalgia Rheumatica 5 2024-11-19
A research study to evaluate the effects of a new oral medicine called cenerimod in adults with systemic lupus erythematosus Ended

2024-515870-28-00 Moderate to severe systemic lupus erythematosus 5 2024-10-22
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended

2023-503923-24-00 Sjögren’s Syndrome With Moderate-toSevere Symptom State 5 2024-07-22
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. Ended

2022-501480-41-00 Psoriatic Arthritis 5 2023-04-06
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Moderately to Severely Active Crohn's Disease 4 2022-11-30
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t… Ended

2023-504737-41-00 Moderately to Severely Active Crohn's Disease 5 2022-06-10
Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus Ended

2024-513031-24-00 Moderate-to-severe Systemic Lupus Erythematosus (SLE) 10 2021-10-22
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended

2023-506256-25-00 Active Psoriatic Arthritis 5 2021-10-20
A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended

2023-506368-14-00 Systemic lupus erythematosus (SLE) 5 2021-09-07
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended

2023-504734-21-00 Psoriatic arthritis (PsA) 5 2021-08-30
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended

2023-504716-15-00 Psoriatic Arthritis 6 2021-08-06
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth… Ended

2022-501017-31-00 Rheumatoid arthritis 5 2016-05-10